ReviewCancers2022
Cytopenia after CAR-T Cell Therapy-A Brief Review of a Complex Problem.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.Blood advances · 2025Pooled it
- Efficacy and safety of early antibiotic de-escalation in febrile neutropenia for patients with hematologic malignancy: a systematic review and meta-analysis.Antimicrobial agents and chemotherapy · 2025Pooled it
- A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.International journal of hematology · 2023Trial
- Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review-NEW Group (Neutropenic Events Working Group).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Small-molecule control of CAR T cells.Nature reviews. Chemistry · 2025Review
- CAR-T cell therapy in nephrology.Renal failure · 2025Review
- Deciphering the Complex Intertwining Between Cytopenia and Transfusion Needs After CAR-T-Cell Therapy for B-Cell Malignancies.Life (Basel, Switzerland) · 2025Article
- Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in Malaysia.Bone marrow transplantation · 2025Article
- Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.Drug safety · 2025Review
- CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.Journal for immunotherapy of cancer · 2025Review
- Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer.Experimental hematology & oncology · 2025Review
- Cellular sentinels: empowering survival and immune defense in hematopoietic stem cell transplantation through mesenchymal stem cells and T lymphocytes.BMC medicine · 2025Article
- Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.Blood advances · 2025Article
- Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy.Research (Washington, D.C.) · 2025Review
- Prolonged Cytopenia with CAR-T Cell Therapy and Management Recommendations.Clinical hematology international · 2025Article
- CAR T-cell therapy to treat multiple myeloma: current state and future directions.Cancer metastasis reviews · 2024Review
- Prolonged severe cytopenia followed by fatal CAR T-cell-mediated encephalitis in a patient with acute lymphoblastic leukemia.Blood cell therapy · 2024Article
- New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.Experimental hematology & oncology · 2024Review
- Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation.Haematologica · 2024Article
- Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.Blood advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy has emerged as an efficacious and life extending treatment modality with high response rates and durable remissions in patients with relapsed and refractory non-Hodgkin lymphoma (NHL), follicular lymphoma, and B-cell acute lymphoblastic leukemia (B-ALL) as well as in other diseases. Prolonged or recurrent cytopenias after CAR-T therapy have increasingly been reported at varying rates, and the pathogenesis of this complication is not yet well-understood but is likely contributed to by multiple factors. Current studies reported are primarily retrospective, heterogeneous in terms of CAR-Ts used and diseases treated, non-uniform in definitions of cytopenias and durations for end points, and vary in terms of recommended management. Prospective studies and correlative laboratory studies investigating the pathophysiology of prolonged cytopenias will enhance our understanding of this phenomenon. This review summarizes knowledge of these cytopenias to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.